Remus Pharmaceuticals Limited — Investor Meet, 23-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Remus Pharmaceuticals reported H2 revenues of Rs.41.49 Cr (+14% YoY) and net profit of Rs.10.71 Cr (+22% YoY). FY25 standalone revenues grew 23% to Rs.79.16 Cr, with net profit at Rs.19.90 Cr (+18% YoY). Consolidated revenues jumped 191% to Rs.620.36 Cr due to full consolidation of the US subsidiary. Management is expanding B2C presence, aiming to lift its share to 25-30% of revenues from 10-15%, supporting margin improvement. New molecule filings and a Singapore office plan reflect a push for global growth and branded generics in emerging markets.